Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Jefferies Group dropped their Q3 2017 earnings per share estimates for Esperion Therapeutics in a report released on Tuesday. Jefferies Group analyst M. Yee now anticipates that the biopharmaceutical company will post earnings per share of ($2.02) for the quarter, down from their prior estimate of ($1.40). Jefferies Group currently has a “Buy” rating and a $55.00 target price on the stock. Jefferies Group also issued estimates for Esperion Therapeutics’ Q4 2017 earnings at ($2.22) EPS, FY2017 earnings at ($7.96) EPS and FY2018 earnings at ($8.72) EPS.

Other equities analysts have also recently issued reports about the stock. UBS AG reiterated a “buy” rating and set a $57.00 target price (up from $52.00) on shares of Esperion Therapeutics in a research note on Tuesday, June 27th. Zacks Investment Research cut shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 target price (up from $60.00) on shares of Esperion Therapeutics in a research note on Thursday. Needham & Company LLC upped their target price on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a research note on Tuesday. Finally, BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Sunday, June 25th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $41.16.

COPYRIGHT VIOLATION WARNING: “Jefferies Group Weighs in on Esperion Therapeutics, Inc.’s Q3 2017 Earnings (ESPR)” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/11/jefferies-group-weighs-in-on-esperion-therapeutics-inc-s-q3-2017-earnings-espr.html.

Esperion Therapeutics (ESPR) opened at 48.14 on Friday. The firm’s market capitalization is $1.09 billion. Esperion Therapeutics has a one year low of $9.40 and a one year high of $57.38. The firm’s 50-day moving average is $46.88 and its 200 day moving average is $34.99.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.67) by $0.25. During the same period in the prior year, the business earned ($0.62) EPS.

Large investors have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at about $158,000. C WorldWide Group Holding A S acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at about $162,000. Princeton Alpha Management LP acquired a new stake in shares of Esperion Therapeutics during the first quarter valued at about $205,000. Bank of Montreal Can raised its stake in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the period. Finally, Aperio Group LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter valued at about $249,000. 85.20% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.